Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0DV6D
|
|||
| Drug Name |
Darolutamide
|
|||
| Synonyms |
1297538-32-9; BAY-1841788; N-((S)-1-(3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide; Darolutamide [USAN]; Darolutamide (JAN/USAN/INN); SCHEMBL1814935; SCHEMBL13733117; KS-00000TSX; EX-A759; BLIJXOOIHRSQRB-PXYINDEMSA-N; MolPort-046-033-692; MolPort-044-560-277; AKOS030526387; CS-5174; BAY1841788; DB12941; BAY 1841788; HY-16985; S7559; FT-0700158; J3.501.129C; D11045; J-690121; 1H-Pyrazole-3-carboxamide, N-((1S)-2-(3-(3-chloro-4-cyanophen
Click to Show/Hide
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Approved | [1] | |
| Company |
Bayer Pharmaceuticals Whippany, NJ
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H19ClN6O2
|
|||
| Canonical SMILES |
CC(CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O
|
|||
| InChI |
1S/C19H19ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11-12,27H,10H2,1-2H3,(H,22,28)(H,23,24)/t11-,12?/m0/s1
|
|||
| InChIKey |
BLIJXOOIHRSQRB-PXYINDEMSA-N
|
|||
| CAS Number |
CAS 1297538-32-9
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.